Type 1 Diabetes

Type 1 diabetes incidence among children under 18 years of age in Israel increased by 6% per annum between 2000 and 2008. Among children under 5 years of age, it increased by 104% in 6 years. The authors suggested that viral infections could be one of the factors in the disease, which mean that rotavirus vaccination might reduce the risk of diabetes. It turned out, however, that there were 7.4 times more vaccinated than unvaccinated among type 1 diabetes patients.

Analysis of clinical trial data from Hib vaccine in Finland (116,000 children.) The Hib vaccine increases the risk of juvenile diabetes by 26%. Diabetes began 38 months after vaccination. The vaccine was also tested on diabetes-prone mice In vaccinated mice, diabetes developed more often.In other studies, a similar increased risk of diabetes was detected, but since these studies were small, the results were not statistically significant.

Even this side effect (an increased risk of juvenile diabetes) exceeds the benefit of the vaccine, which should prevent 7 deaths and 7-26 disability cases per 100,000 vaccinated. For every child rescued from Hib, there will be four people with diabetes.In the US and the UK, the number of cases of diabetes has increased dramatically after the onset of Hib vaccination, especially among children under the age of 4. The authors conclude that the potential harm of the vaccine is greater than the potential benefit. More: [1].

Vaccine research is based on the theory that the benefits of vaccination far outweigh the risks of long-term side effects, and therefore there is no need for long-term safety studies. We found that only the increased risk of only one complication (diabetes) outweighs reduced risk of meningitis.We believe that the public should be informed that vaccines can lead to long-term complications.This will lead to the fact that the public will require more adequate research Security tions prior to vaccination, which, in turn, will lead to the development of safer vaccines.

Hib vaccine increases 5.9 times the risk of antibodies to GAD, and 3.4 times antibodies to IA-2, which are considered autoimmune markers for the development of type 1 diabetes.

Content above is licenced under Creative Common Attribution—NonCommercial—NoDerivatives (CC BY-NC-ND) licence,
i.e. it is free for non-commercial distribution and citation with this reference being provided: scibook.org, amantonio,
using the content to create another product or meaning is prohibited.